Yonhap Infomax NewsCelltrion Chairman Seo Jung-jin announced the company has been named preferred bidder for a major US pharmaceutical plant, aiming to hedge tariff risks and secure exclusive production rights, with 2025 sales guidance largely unchanged at 4.5–4.6 trillion won.
#YonhapInfomax
#Celltrion #SeoJungJin #USPharmaceuticalPlant #TariffRisk #SalesGuidance
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=74283
#YonhapInfomax
#Celltrion #SeoJungJin #USPharmaceuticalPlant #TariffRisk #SalesGuidance
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=74283
Celltrion Chairman Seo Jung-jin Says 'Selected as Preferred Bidder for US Plant—Tariff Uncertainty Eliminated'
Celltrion Chairman Seo Jung-jin announced the company has been named preferred bidder for a major US pharmaceutical plant, aiming to hedge tariff risks and secure exclusive production rights, with 2025 sales guidance largely unchanged at 4.5–4.6 trillion won.